FdaApplication
NDA 214094
Identifiers
- fda_app_no: NDA214094
Properties
| Property | Value |
|---|---|
| applicant_name | BIOCRYST PHARMACEUTICALS INC |
| application_type | NDA |
| approval_date | 2020-12-03 |
Revenue by product
ORLADEYO
| Period | Revenue |
|---|---|
| Q3 2024 | $116.3M |
| Q3 2023 | $85.7M |
| Q3 2022 | $66.0M |
Revenue as this company reported it for this product. A combination product's amount is stated once, for the product, and never divided across its ingredients.
Products (2)
| Product | Active ingredient | Strength | Dosage form |
|---|---|---|---|
| ORLADEYO | BEROTRALSTAT DIHYDROCHLORIDE | EQ 150MG BASE | CAPSULE;ORAL |
| ORLADEYO | BEROTRALSTAT DIHYDROCHLORIDE | EQ 110MG BASE | CAPSULE;ORAL |
2 products